All Studies Meta Analysis

Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving Monoclonal Antibodies

Wilden et al., Journal of the National Comprehensive Cancer Network, doi:10.6004/jnccn.2021.7309

Mar 2022

Post
Facebook

Source PDF All Studies Meta AnalysisMeta

Download Image

Casirivimab/imdevimab

17th treatment shown to reduce risk in March 2021, now with p = 0.00036 from 31 studies, recognized in 45 countries. Efficacy is variant dependent.

Lower risk for hospitalization, progression, recovery, cases, and viral clearance.

No treatment is 100% effective. Protocols combine treatments.

5,100+ studies for 112 treatments. c19early.org

Retrospective 395 patients in the USA receiving casirivimab/imdevimab or bamlanivimab, showing lower risk of hospitalization with treatment, statistically significant for casirivimab/imdevimab.

Efficacy is variant dependent. In Vitro research suggests a lack of efficacy for many omicron variants1-7.

Important missing comments or errors? Let us know.

Study covers bamlanivimab/etesevimab and casirivimab/imdevimab.

risk of hospitalization, 82.0% lower, OR 0.18, p = 0.004, adjusted per study, multivariable, RR approximated with OR.

Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates

1. Liu et al., Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2, bioRxiv, doi:10.1101/2021.12.14.472719.biorxiv.org, doi.org.

2. Sheward et al., Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron), bioRxiv, doi:10.1101/2021.12.19.473354.biorxiv.org, doi.org.

3. VanBlargan et al., An infectious SARS-CoV-2 B.1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies, bioRxiv, doi:10.1101/2021.12.15.472828.biorxiv.org, doi.org.

4. Tatham et al., Lack of Ronapreve (REGN-CoV; casirivimab and imdevimab) virological efficacy against the SARS-CoV 2 Omicron variant (B.1.1.529) in K18-hACE2 mice, bioRxiv, doi:10.1101/2022.01.23.477397.biorxiv.org, doi.org.

5. Pochtovyi et al., In Vitro Efficacy of Antivirals and Monoclonal Antibodies against SARS-CoV-2 Omicron Lineages XBB.1.9.1, XBB.1.9.3, XBB.1.5, XBB.1.16, XBB.2.4, BQ.1.1.45, CH.1.1, and CL.1, Vaccines, doi:10.3390/vaccines11101533.mdpi.com, doi.org.

6. Haars et al., Prevalence of SARS-CoV-2 Omicron Sublineages and Spike Protein Mutations Conferring Resistance against Monoclonal Antibodies in a Swedish Cohort during 2022–2023, Microorganisms, doi:10.3390/microorganisms11102417.mdpi.com, doi.org.

7. Uraki et al., Antiviral efficacy against and replicative fitness of an XBB.1.9.1 clinical isolate, iScience, doi:10.1016/j.isci.2023.108147.sciencedirect.com, doi.org.

Wilden et al., 31 Mar 2022, retrospective, USA, peer-reviewed, 9 authors, study period December 2020 - July 2021.

This Paper Casirivimab/i..All

{ 'indexed': {'date-parts': [[2022, 4, 4]], 'date-time': '2022-04-04T00:56:40Z', 'timestamp': 1649033800757}, 'reference-count': 0, 'publisher': 'Harborside Press, LLC', 'issue': '3.5', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'short-container-title': [], 'published-print': {'date-parts': [[2022, 3, 31]]}, 'DOI': '10.6004/jnccn.2021.7309', 'type': 'journal-article', 'created': {'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T11:49:36Z', 'timestamp': 1648727376000}, 'page': 'HSR22-178', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': [ 'HSR22-178: Real World Outcomes of Cancer Patients With SARS-CoV-2 Infection Receiving ' 'Monoclonal Antibodies'], 'prefix': '10.6004', 'volume': '20', 'author': [ { 'given': 'Alexa', 'family': 'Wilden', 'sequence': 'first', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Aishwarya', 'family': 'Sannareddy', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Hetal', 'family': 'Patel', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Shraddha', 'family': 'Kansagra', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Gurbakhash', 'family': 'Kaur', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Praveen', 'family': 'Ramakrishnan', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Prapti', 'family': 'Patel', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}, { 'given': 'Ansh', 'family': 'Mehta', 'sequence': 'additional', 'affiliation': [{'name': '2 Jacobi Medical Center, Bronx, NY'}]}, { 'given': 'Ankit', 'family': 'Kansagra', 'sequence': 'additional', 'affiliation': [{'name': '1 UT Southwestern Medical Center, Dallas, TX'}]}], 'member': '4047', 'container-title': ['Journal of the National Comprehensive Cancer Network'], 'original-title': [], 'link': [ { 'URL': 'https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml', 'content-type': 'text/html', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 3, 31]], 'date-time': '2022-03-31T11:50:05Z', 'timestamp': 1648727405000}, 'score': 1, 'resource': {'primary': {'URL': 'https://jnccn.org/view/journals/jnccn/20/3.5/article-pHSR22-178.xml'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 3, 31]]}, 'references-count': 0, 'journal-issue': {'issue': '3.5'}, 'URL': 'http://dx.doi.org/10.6004/jnccn.2021.7309', 'relation': {}, 'ISSN': ['1540-1405', '1540-1413'], 'issn-type': [{'value': '1540-1405', 'type': 'print'}, {'value': '1540-1413', 'type': 'electronic'}], 'subject': ['Oncology'], 'published': {'date-parts': [[2022, 3, 31]]}}

Download Image

Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.

Submit

Post

@CovidAnalysis

FAQ

Public domain CC0 1.0